PBS updates

Opdivo (Nivolumab)

nivolumab 100 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 13240W

AUTHORITY_REQUIRED

What it costs

AU$1972.83 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2023-04-01.
  • • Repeats: 5.
  • • PBS program: IP.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Adjuvant treatment of stage II or III oesophageal cancer or gastro-oesophageal junction cancer


The condition must have histological evidence confirming a diagnosis of a least one of: (i) adenocarcinoma, (ii) squamous cell cancer; document this evidence in the patient's medical records; AND

The condition must have been treated with neoadjuvant platinum-based chemoradiotherapy; AND

The treatment must be for the purposes of adjuvant use following complete surgical resection that occurred within 16 weeks prior to initiating this drug; AND

The condition must have evidence, through resected specimen, that residual disease meets the Tumour Nodes Metastases (TNM) staging system (as published by the Union for International Cancer Control) of either: (i) at least ypT1, (ii) at least ypN1; document this evidence in the patient's medical records; AND

Patient must have/have had, at the time of initiating treatment with this drug, a WHO performance status no higher than 1; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must be undergoing treatment with a dosing regimen as set out in the drug's approved Australian Product Information; AND

Patient must not be undergoing PBS-subsidised treatment with this drug where this prescription extends treatment beyond whichever comes first: (i) 12 months from treatment initiation, irrespective of whether initial treatment was PBS-subsidised/non-PBS-subsidised, (ii) disease recurrence despite treatment with this drug; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.